ZVSA
ZyVersa Therapeutics, Inc.
1W: +4.5%
1M: -11.5%
3M: +70.4%
YTD: +70.4%
1Y: -62.2%
3Y: -100.0%
$0.20
+0.00 (+0.00%)
Weekly Expected Move ±14.2%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.6M
52W Range0.11-1.94
Volume9,575
Avg Volume73,390
Beta0.65
Dividend—
Analyst Ratings
Company Info
CEOStephen C. Glover
Employees7
SectorHealthcare
IndustryBiotechnology
IPO Date2022-02-11
Websitezyversa.com
2200 N. Commerce Parkway
Weston, FL 33326
US
Weston, FL 33326
US
754 231 1688
About ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Latest News
ZyVersa Therapeutics GAAP EPS of -$4.18
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
ZyVersa Therapeutics (NASDAQ:ZVSA) Stock Price Up 3.8% – Here’s What Happened
ZyVersa Therapeutics (NASDAQ:ZVSA) Shares Up 65.4% – Still a Buy?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Cashmere Karen A. | A-Award | 48,100 | $0.59 | 2025-07-11 |
| Freitag Gregory Gene | A-Award | 11,066 | $0.59 | 2025-07-11 |
| Glover Stephen C. | A-Award | 136,900 | $0.59 | 2025-07-11 |
| Finizio Robert G | A-Award | 11,066 | $0.59 | 2025-07-11 |
| Wolfe Peter | A-Award | 60,100 | $0.59 | 2025-07-11 |